These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
144 related items for PubMed ID: 18462801
1. Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: a database review and analysis. Dumotier BM, Deurinck M, Yang Y, Traebert M, Suter W. Pharmacol Ther; 2008 Aug; 119(2):152-9. PubMed ID: 18462801 [Abstract] [Full Text] [Related]
2. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Gintant G. Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552 [Abstract] [Full Text] [Related]
3. BeKm-1, a peptide inhibitor of human ether-a-go-go-related gene potassium currents, prolongs QTc intervals in isolated rabbit heart. Qu Y, Fang M, Gao B, Chui RW, Vargas HM. J Pharmacol Exp Ther; 2011 Apr; 337(1):2-8. PubMed ID: 21205913 [Abstract] [Full Text] [Related]
4. The anesthetized guinea pig: an effective early cardiovascular derisking and lead optimization model. Morissette P, Nishida M, Trepakova E, Imredy J, Lagrutta A, Chaves A, Hoagland K, Hoe CM, Zrada MM, Travis JJ, Zingaro GJ, Gerenser P, Friedrichs G, Salata JJ. J Pharmacol Toxicol Methods; 2013 Apr; 68(1):137-49. PubMed ID: 23649000 [Abstract] [Full Text] [Related]
5. Drug-induced QT interval prolongation--regulatory guidance and perspectives on hERG channel studies. Shah RR. Novartis Found Symp; 2005 Apr; 266():251-80; discussion 280-5. PubMed ID: 16050273 [Abstract] [Full Text] [Related]
6. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs. Nogawa H, Kawai T, Yajima M, Miura M, Ogawa T, Murakami K. Eur J Pharmacol; 2013 Nov 15; 720(1-3):29-37. PubMed ID: 24211675 [Abstract] [Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys. Watson KJ, Gorczyca WP, Umland J, Zhang Y, Chen X, Sun SZ, Fermini B, Holbrook M, Van Der Graaf PH. J Pharmacol Toxicol Methods; 2011 Nov 15; 63(3):304-13. PubMed ID: 21419854 [Abstract] [Full Text] [Related]
9. In vivo effects of the IKr agonist NS3623 on cardiac electrophysiology of the guinea pig. Hansen RS, Olesen SP, Rønn LC, Grunnet M. J Cardiovasc Pharmacol; 2008 Jul 15; 52(1):35-41. PubMed ID: 18594476 [Abstract] [Full Text] [Related]
10. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Gintant GA. Pharmacol Ther; 2008 Aug 15; 119(2):199-209. PubMed ID: 18621077 [Abstract] [Full Text] [Related]
11. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Chen X, Cass JD, Bradley JA, Dahm CM, Sun Z, Kadyszewski E, Engwall MJ, Zhou J. Br J Pharmacol; 2005 Nov 15; 146(6):792-9. PubMed ID: 16158069 [Abstract] [Full Text] [Related]
12. The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Hancox JC, McPate MJ, El Harchi A, Zhang YH. Pharmacol Ther; 2008 Aug 15; 119(2):118-32. PubMed ID: 18616963 [Abstract] [Full Text] [Related]
13. Isolated perfused and paced guinea pig heart to test for drug-induced changes of the QT interval. Cheng HC, Incardona J, McCullough B. J Pharmacol Toxicol Methods; 2006 Aug 15; 54(3):278-87. PubMed ID: 16507347 [Abstract] [Full Text] [Related]
14. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). Ducroq J, Moha ou Maati H, Guilbot S, Dilly S, Laemmel E, Pons-Himbert C, Faivre JF, Bois P, Stücker O, Le Grand M. Br J Pharmacol; 2010 Jan 15; 159(1):93-101. PubMed ID: 19703166 [Abstract] [Full Text] [Related]
15. QT PRODACT: evaluation of the potential of compounds to cause QT interval prolongation by action potential assays using guinea-pig papillary muscles. Kii Y, Hayashi S, Tabo M, Shimosato T, Fukuda H, Itoh T, Amano H, Saito M, Morimoto H, Yamada K, Kanda A, Ishitsuka T, Yamazaki T, Kiuchi Y, Taniguchi S, Mori T, Shimizu S, Tsurubuchi Y, Yasuda S, Kitani S, Shimada C, Kobayashi K, Komeno M, Kasai C, Hombo T, Yamamoto K. J Pharmacol Sci; 2005 Jan 15; 99(5):449-57. PubMed ID: 16493186 [Abstract] [Full Text] [Related]
16. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499. Chaves AA, Zingaro GJ, Yordy MA, Bustard KA, O'Sullivan S, Galijatovic-Idrizbegovic A, Schuck H, Christian DB, Hoe CM, Briscoe RJ. J Pharmacol Toxicol Methods; 2007 Jan 15; 56(2):103-14. PubMed ID: 17643323 [Abstract] [Full Text] [Related]
18. Evidence for a crucial modulating role of the sodium channel in the QTc prolongation related to antipsychotics. Silvestre JS, O'Neill MF, Prous JR. J Psychopharmacol; 2014 Apr 15; 28(4):329-40. PubMed ID: 24327451 [Abstract] [Full Text] [Related]
19. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium. Park E, Gintant GA, Bi D, Kozeli D, Pettit SD, Pierson JB, Skinner M, Willard J, Wisialowski T, Koerner J, Valentin JP. Br J Pharmacol; 2018 Feb 15; 175(4):606-617. PubMed ID: 29181850 [Abstract] [Full Text] [Related]
20. Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model. Yao X, Anderson DL, Ross SA, Lang DG, Desai BZ, Cooper DC, Wheelan P, McIntyre MS, Bergquist ML, MacKenzie KI, Becherer JD, Hashim MA. Br J Pharmacol; 2008 Aug 15; 154(7):1446-56. PubMed ID: 18587422 [Abstract] [Full Text] [Related] Page: [Next] [New Search]